Skip to content
← Childhood Acute Promyelocytic Leukemia

HEALTH PROFESSIONAL · SOURCE READING

Arsenic Trioxide With or Without Tretinoin

Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: June 14, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Recurrent APL

For children with recurrent APL, the use of arsenic trioxide as a single agent or in regimens including tretinoin should be considered, depending on the therapy given during first remission. Arsenic trioxide is an active agent in adult patients with recurrent APL, with approximately 85% to 94% of patients achieving remission after treatment with this agent.[8-13] More limited data in children suggest that children with relapsed APL have a response to arsenic trioxide that is similar to that of adults.[8,10,13,14] Arsenic trioxide is well tolerated in children with relapsed APL, with a toxicity profile similar to that of adults.[8,13]

Source links and citations

Arsenic trioxide is capable of inducing remissions in patients who relapse after having received arsenic trioxide with or without other agents during initial therapy.[13,15] However, APL cells may develop arsenic trioxide resistance when they acquire somatic variants in the PML domain of the PML::RARA fusion oncogene.[16]

Source links and citations

Because arsenic trioxide causes QT-interval prolongation that can lead to life-threatening arrhythmias,[17] it is essential to monitor electrolytes closely in patients receiving arsenic trioxide and to maintain potassium and magnesium values at midnormal ranges.[18]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice